{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T21:45:15Z","timestamp":1773697515905,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12879-019-4197-7","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T11:02:54Z","timestamp":1561028574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases"],"prefix":"10.1186","volume":"19","author":[{"given":"Jackie","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Mudaly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Voget","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey","family":"Naledi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Maartens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1892-4207","authenticated-orcid":false,"given":"Karen","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,20]]},"reference":[{"key":"4197_CR1","unstructured":"WHO Global Tuberculosis Report [\n                    http:\/\/apps.who.int\/iris\/bitstream\/10665\/259366\/1\/9789241565516-eng.pdf?ua=1\n                    \n                  ]."},{"key":"4197_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1183\/13993003.01891-2015","volume":"47","author":"E Pontali","year":"2016","unstructured":"Pontali E, Sotgiu G, D'Ambrosio L, Centis R, Migliori GB. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J. 2016;47:394\u2013402.","journal-title":"Eur Respir J"},{"key":"4197_CR3","unstructured":"FDA Bedaquiline accelerated approval letter [\n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/204384orig1s000ltr.pdf\n                    \n                  ]."},{"key":"4197_CR4","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","volume":"371","author":"A Diacon","year":"2009","unstructured":"Diacon A, Pym A, Grobusch M. The diarylquinoline TMC207 for multridrug-resistant tuberculosis. New Engl J Med. 2009;371:2397\u2013405.","journal-title":"New Engl J Med"},{"key":"4197_CR5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1313865","volume":"371","author":"A Diacon","year":"2014","unstructured":"Diacon A, Pym A, Grobusch M. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. New Engl J Med. 2014;371:723\u201332.","journal-title":"New Engl J Med"},{"key":"4197_CR6","unstructured":"WHO interim policy guidance: the use of bedaquiline in the treatment of multidrug-resistant tuberculosis [\n                    http:\/\/apps.who.int\/iris\/bitstream\/10665\/84879\/1\/9789241505482_eng.pdf\n                    \n                  ]."},{"key":"4197_CR7","unstructured":"Sirturo (bedaquiline) full prescribing information [\n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/204384s000lbl.pdf\n                    \n                  ]."},{"issue":"8","key":"4197_CR8","doi-asserted-by":"publisher","first-page":"979","DOI":"10.5588\/ijtld.14.0944","volume":"19","author":"N Ndjeka","year":"2015","unstructured":"Ndjeka N, Conradie F, Schnippel K, Hughes J, Bantubani N, Ferreira H, Maartens G, Mametja D, Meintjes G, Padanilam X, et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tuberc Lung Dis. 2015;19(8):979\u201385.","journal-title":"Int J Tuberc Lung Dis"},{"key":"4197_CR9","unstructured":"Guidelines for implementation of new DR_TB drug regimen. In.; 2015."},{"issue":"4","key":"4197_CR10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1365-2125.2009.03595.x","volume":"69","author":"J Taubel","year":"2010","unstructured":"Taubel J, Naseem A, Harada T, Wang D, Arezina R, Lorch U, Camm AJ. Levofloxacin can be used effectively as a positive control in thorough QT\/QTc studies in healthy volunteers. Br J Clin Pharmacol. 2010;69(4):391\u2013400.","journal-title":"Br J Clin Pharmacol"},{"key":"4197_CR11","unstructured":"The use of the WHO-UMC system for standardised case causality assessment. [\n                    http:\/\/www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/WHOcausality_assessment.pdf\n                    \n                  ]."},{"issue":"6","key":"4197_CR12","first-page":"538","volume":"27","author":"G Schumock","year":"1992","unstructured":"Schumock G, Thornton J. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27(6):538.","journal-title":"Hosp Pharm"},{"key":"4197_CR13","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1183\/13993003.00724-2015","volume":"47","author":"A Pym","year":"2016","unstructured":"Pym A, Diacon A, Tang S-J, Conradie F, Danilovits M, Chuchottaworn C, Vasilyeva I, Andries K, Bakare N, De Marez T, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2016;47:564\u201374.","journal-title":"Eur Respir J"},{"issue":"3","key":"4197_CR14","doi-asserted-by":"publisher","first-page":"1601799","DOI":"10.1183\/13993003.01799-2016","volume":"49","author":"L Guglielmetti","year":"2017","unstructured":"Guglielmetti L, Jaspard M, Le Du D, Lachatre M, Marigot-Outtandy D, Bernard C, Veziris N, Robert J, Yazdanpanah Y, Caumes E, et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J. 2017;49(3):1601799.","journal-title":"Eur Respir J"},{"issue":"5","key":"4197_CR15","doi-asserted-by":"publisher","first-page":"1701462","DOI":"10.1183\/13993003.01462-2017","volume":"50","author":"Emanuele Pontali","year":"2017","unstructured":"Pontali E, Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Migliori GB. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Eur Respir J. 2017;50(50).","journal-title":"European Respiratory Journal"},{"issue":"9","key":"4197_CR16","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S2213-2600(18)30235-2","volume":"6","author":"Kathryn Schnippel","year":"2018","unstructured":"Schnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, Ismail N, Hughes J, Ferreira H, Padanilam X, Romero R, et al. Effect of bedaquiline on mortality in south African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med. 2018;6(9):699\u2013706.","journal-title":"The Lancet Respiratory Medicine"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4197-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4197-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4197-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T13:28:12Z","timestamp":1596115692000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4197-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,20]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4197"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4197-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,20]]},"assertion":[{"value":"3 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The repository and this case series have approval from the University of Cape Town Health Sciences Research Ethics Committee (R040\/2016; HREC 318\/2017). Requirement for informed consent was waived by the ethics committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"544"}}